乳腺增生病雌、孕激素受体表达及临床意义

目的:探讨乳腺增生病变组织中雌、孕激素受体表达情况,及其临床意义。方法:将乳腺增生病患者手术切除标本,常规福尔马林固定,石蜡包埋,采用免疫组化S-P法,测定ER、PR表达。结果ER和PR总阳性率74.36%(27/39)和87.18%(34/39),ER、PR同时阳性为66.67%(26/39)。本组不典型增生6例ER和PR阳性率均为100%,其表达强度最强,其次为腺病伴腺瘤形成,最弱为小叶增生。结论:乳腺增生病变组织中ER、PR虽然呈高表达,是三苯氧胺(TAM)治疗的适应症,但仍有25.64%的患者ER呈阴性表达,因此,用TAM治疗乳腺增生病前应检测患者的ER和PR,阳性者可用TAM治疗。

Clinical siginficance and expression of ER and PR in breast cancer

Objective: To investigate the expression of estrogen receptor(ER) and progesterone receptor(PR) in breast cancer and the clinical significance. Methods: Detect ER and PR in 39 cases paraffin specimens of females with breast cancer by immunohistochemical staining. Results: The positive rates of ER and PR expression in 39 cases were 74.36% and 87.18% respectively.Both ER and PR positive vate was 66.67%, 6 cases with atipical ductal epithelial hyperplasia were 100% positive .The cases of lobular hyperplasia were the most weak expressed, 3 cases with apocrine metaplasia were positive only for ER. Clonclusion: ER and PR are high positive expression with breast cancer, and are indication for cinical treatment of endocrine(TAM), but 25.64% of cases showed negative. ER and PR should be examnated before using TAM.